IFLR1000

Shire $5.9 billion acquisition of Dyax

22/1/2016
Public acquisition
Select tab

$ 5.9 billion

Completed

22/1/2016

Overview:

  • Dublin-based pharmaceutical company Shire has completed its $5.9 billion acquisition of Dyax.
  • Dyax focuses on developing treatments for rare diseases. 
  • The deal was first announced in November 2015, less than a year after the completion of Shire's acquisition of NPS Pharmaceuticals. 
  • Morgan Stanley, Deutsche Bank and Evercore acted as financial advisers for Shire, while Centerview Partners served as financial adviser for Dyax. 

Kurt Stumpo - Journalist

Jurisdictions:

United States
Ireland

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Latham & Watkins

Party: Centerview Partners (Financial adviser)

Lawyer: Charles Ruck

Ropes & Gray

Party: Shire (Acquirer)

Lawyers: Christopher Comeau, Paul Kinsella

Slaughter and May

Party: Shire (Acquirer)

Lawyer: Azadeh Nassiri

Sullivan & Cromwell

Party: Dyax (Target)

Lawyer: Matthew Friestedt

Related deals